EPS (Diluted) for IDEXX Laboratories (IDXX)
According to IDEXX Laboratories's latest reported financial statements, the company's current diluted EPS (TTM) is $13.07. Diluted earnings per share (EPS) is net income divided by the diluted weighted-average shares outstanding over the period. It expresses profit on a per-share basis — the figure investors use to value an individual share — and accounts for potential dilution from options, RSUs, and convertible securities.
Headline TTM above sums the four reported quarters through (reported ). Chart and table below cover the full reported history back to .
Currently viewingEPS (Diluted)Switch metric
TTM (last 4 quarters)
$13.07
YoY change
+22.6%
5Y CAGR
+14.3%
Peak year (2025)
$13.08
Latest annual
$13.08
EPS (Diluted) history chart for IDEXX Laboratories (IDXX) from 1991 to 2025
EPS (Diluted) history table for IDEXX Laboratories (IDXX) from 1991 to 2025
| Fiscal year | Period ended | Reported | EPS (Diluted) | YoY |
|---|---|---|---|---|
| 2025 | $13.08 | +22.6% | ||
| 2024 | $10.67 | +6.1% | ||
| 2023 | $10.06 | +25.3% | ||
| 2022 | $8.03 | -6.6% | ||
| 2021 | $8.60 | +28.2% | ||
| 2020 | $6.71 | +37.2% | ||
| 2019 | $4.89 | +14.8% | ||
| 2018 | $4.26 | +44.9% | ||
| 2017 | $2.94 | +20.5% | ||
| 2016 | $2.44 | +19.0% | ||
| 2015 | $2.05 | +14.5% | ||
| 2014 | $1.79 | +2.9% | ||
| 2013 | $1.74 | +9.4% | ||
| 2012 | $1.59 | +14.4% | ||
| 2011 | $1.39 | +16.8% | ||
| 2010 | $1.19 | +19.0% | ||
| 2009 | $1.00 | +6.4% | ||
| 2008 | $0.94 | +28.8% | ||
| 2007 | $0.73 | +2.8% | ||
| 2006 | $0.71 | +24.6% | ||
| 2005 | $0.57 | +3.6% | ||
| 2004 | $0.55 | +37.5% | ||
| 2003 | $0.40 | +21.2% | ||
| 2002 | $0.33 | +22.2% | ||
| 2001 | $0.27 | +3.8% | ||
| 2000 | $0.26 | +23.8% | ||
| 1999 | $0.21 | -310.0% | ||
| 1998 | $-0.10 | -28.6% | ||
| 1997 | $-0.14 | -166.7% | ||
| 1996 | $0.21 | +40.0% | ||
| 1995 | $0.15 | +50.0% | ||
| 1994 | $0.10 | +37.9% | ||
| 1993 | $0.07 | +61.1% | ||
| 1992 | $0.04 | +12.5% | ||
| 1991 | $0.04 | — |
EPS (Diluted) values are taken from IDEXX Laboratories's reported income statements (10-Q quarterly and 10-K annual filings with the U.S. Securities and Exchange Commission). Each row shows the period end date and the date the filing was reported; YoY compares each figure to the same period one year earlier. Amounts are in USD as filed.
Analysis
In 2025, IDEXX Laboratories (IDXX) diluted EPS totalled $13.08 – grew 22.6% year-over-year.
Across 2020–2025 (5 years), IDEXX Laboratories diluted EPS produced a CAGR of +14.3% – sustaining 3 straight years of year-over-year growth.
The dataset's maximum diluted EPS sits at $13.08 (2025); the minimum reading of $-0.14 dates to 1997.
Among 8 Healthcare peers, IDEXX Laboratories (IDXX) ranks 5th; the peer median for diluted EPS is $13.16.
IDEXX Laboratories EPS (Diluted) by Year
IDEXX Laboratories EPS (Diluted) 2025: $13.08
IDEXX Laboratories diluted EPS in 2025 was $13.08, grew 22.6% from 2024. This figure represents the highest annual value in the available history.
IDEXX Laboratories EPS (Diluted) 2024: $10.67
IDEXX Laboratories diluted EPS in 2024 was $10.67, grew 6.1% from 2023.
IDEXX Laboratories EPS (Diluted) 2023: $10.06
IDEXX Laboratories diluted EPS in 2023 was $10.06, grew 25.3% from 2022.
IDEXX Laboratories EPS (Diluted) 2022: $8.03
IDEXX Laboratories diluted EPS in 2022 was $8.03, declined 6.6% below 2021.
IDEXX Laboratories EPS (Diluted) 2021: $8.60
IDEXX Laboratories diluted EPS in 2021 was $8.60.
See more financial history for IDEXX Laboratories (IDXX).
Sector peers — EPS (Diluted)
Companies in the same sector as IDEXX Laboratories, ranked by their latest diluted EPS.
| Company | EPS (Diluted) | Sector |
|---|---|---|
| Novo Nordisk A/S (NVO) | $23.03 | Healthcare |
| Eli Lilly and Company (LLY) | $22.95 | Healthcare |
| Amgen Inc. (AMGN) | $14.23 | Healthcare |
| UnitedHealth Group Incorporated (UNH) | $13.23 | Healthcare |
| AstraZeneca PLC (AZN) | $13.08 | Healthcare |
| Johnson & Johnson (JNJ) | $11.03 | Healthcare |
| Merck & Co., Inc. (MRK) | $7.28 | Healthcare |
| AbbVie Inc. (ABBV) | $2.37 | Healthcare |
Frequently asked questions
What is IDEXX Laboratories's diluted EPS?
- Latest reported diluted EPS for IDEXX Laboratories (IDXX) is $13.07 (period ending December 31, 2025).
How has IDEXX Laboratories diluted EPS changed year-over-year?
- IDEXX Laboratories (IDXX) diluted EPS changed +22.6% year-over-year on the latest annual filing.
What is the long-term growth rate of IDEXX Laboratories diluted EPS?
- IDEXX Laboratories (IDXX) diluted EPS compound annual growth rate is +14.3% over the most recent 5 years available.
When did IDEXX Laboratories diluted EPS hit its highest annual value?
- IDEXX Laboratories diluted EPS reached its highest annual value of $13.08 in 2025.
What was IDEXX Laboratories diluted EPS in 2024?
- IDEXX Laboratories (IDXX) diluted EPS in 2024 was $10.67.
What was IDEXX Laboratories diluted EPS in 2025?
- IDEXX Laboratories (IDXX) diluted EPS in 2025 was $13.08.
Metrics overview
Pick a metric for charts, filings, and peers — each row shows the latest TTM or annual value with year-over-year change.
Explore more
IDXX Overview
Company profile, financial tools, and key metrics
IDXX Revenue Counter
Earns $136.47 every second. See per minute, hour, and day.
IDXX Earnings Counter
Earns $33.60 per second net profit. See per minute, hour, and day.
IDXX Economic Scale
Exceeds Aruba's GDP. Compare with world economies.
IDXX What If Invested
What if you had invested $1,000? See historical returns from any date.
IDXX How It Makes Money
Discover visual breakdown of $4.30B in revenue — where it comes from and where it goes.
IDXX Stock Seasonality
Best and worst months to invest. Historical monthly returns heatmap.
IDXX Price Target Scenarios
Model bear, base, and bull cases with EPS growth and exit P/E — pre-filled from analysts and history.
IDXX Daily Price Character
Explosive · 50.9% historical win rate (green days). Streaks & record days.
IDXX Buybacks
2.25% TTM buyback yield. Shareholder yield & SBC comparison.
IDXX Stock Split History
4 splits on record. Dates, ratios, and cumulative multiple.